Antileukemic properties of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors

References

• Gotto AM Jr, Moon JE. Management of cardiovascular risk: the importance of meeting lipid targets. Am J Cardiol 2012;110(Suppl.): 3A–14A.
   PubMed Web of Science ®Google Scholar
• Sassano A, Platanias LC. Statins in tumor suppression. Cancer Lett 2008;260:11–19.
   PubMed Web of Science ®Google Scholar
• Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012;367:1792–1802.
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425–430.
   PubMed Web of Science ®Google Scholar
• Goedeke L, Fernández-Hernando C. Regulation of cholesterol homeostasis. Cell Mol Life Sci 2012;69:915–930.
   PubMed Web of Science ®Google Scholar
• Porter KE, Turner NA. Statins and myocardial remodelling: cell and molecular pathways. Expert Rev Mol Med 2011;13:e22.
   Web of Science ®Google Scholar
• Dimitroulakos J, Nohynek D, Backway KL, et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood 1999;93:1308–1318.
   PubMed Web of Science ®Google Scholar
• Newman A, Clutterbuck RD, Powles RL, et al. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. Leuk Lymphoma 1997;24:533–537.
   PubMed Web of Science ®Google Scholar
• van der Weide K, de Jonge-Peeters S, Huls G, et al. Treatment with high-dose simvastatin inhibits geranylgeranylation in AML blast cells in a subset of AML patients. Exp Hematol 2012;40:177–186.
   PubMed Web of Science ®Google Scholar
• Kornblau SM, Banker DE, Stirewalt D, et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood 2007;109:2999–3006.
   PubMed Web of Science ®Google Scholar
• Li HY, Appelbaum FR, Willman CL, et al. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 2003;101:3628–3634.
   PubMed Web of Science ®Google Scholar
• Xia Z, Tan MM, Wong WW, et al. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 2001;15:1398–1407.
   PubMed Web of Science ®Google Scholar
• van der Weide K, Korthuis PM, Kuipers F, et al. Heterogeneity in simvastatin-induced cytotoxicity in AML is caused by differences in Ras-isoprenylation. Leukemia 2012;26:845–848.
   PubMed Web of Science ®Google Scholar
• van der Weide K, de Jonge-Peeters SD, Kuipers F, et al. Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34 + acute myeloid leukemia samples. Clin Cancer Res 2009;15:3076–3083.
   PubMed Web of Science ®Google Scholar
• Stirewalt DL, Appelbaum FR, Willman CL, et al. Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. Leuk Res 2003;27:133–145.
   PubMed Web of Science ®Google Scholar
• Sassano A, Katsoulidis E, Antico G, et al. Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res 2007;67: 4524–4532.
   PubMed Web of Science ®Google Scholar
• Sassano A, Lo Iacono M, Antico G, et al. Regulation of leukemic cell differentiation and retinoid-induced gene expression by statins. Mol Cancer Ther 2009;8:615–625.
   Google Scholar
• Sassano A, Altman JK, Gordon LI, et al. Statin-dependent activation of protein kinase Cδ in acute promyelocytic leukemia cells and induction of leukemic cell differentiation. Leuk Lymphoma 2012;53:1779–1784.
   PubMed Web of Science ®Google Scholar
• Kambhampati S, Li Y, Verma A, et al. Activation of protein kinase C delta by all-trans-retinoic acid. J Biol Chem 2003;278:32544–32551.
   PubMed Web of Science ®Google Scholar
• Williams AB, Li L, Nguyen B, et al. Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. Blood 2012;120:3069–3079.
   PubMed Web of Science ®Google Scholar
• Minden MD, Dimitroulakos J, Nohynek D, et al. Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia. Leuk Lymphoma 2001;40:659–662.
   PubMed Web of Science ®Google Scholar
• Faderl S, O’Brien S, Pui CH, et al. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer 2010;116:1165–1176.
   PubMed Web of Science ®Google Scholar
• Stock W. Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010:21–29.
   Google Scholar
• Sheen C, Vincent T, Barrett D, et al. Statins are active in acute lymphoblastic leukaemia (ALL): a therapy that may treat ALL and prevent avascular necrosis. Br J Haematol 2011;155:403–407.
   PubMed Web of Science ®Google Scholar
• Gribben JG, O’Brien S. Update on therapy of chronic lymphocytic leukemia. J Clin Oncol 2011;29:544–550.
   PubMed Web of Science ®Google Scholar
• Winiarska M, Bil J, Wilczek E, et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 2008;5:e64.
   PubMed Web of Science ®Google Scholar
• Vitols S, Angelin B, Juliusson G. Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humans--in vitro and in vivo studies. Lipids 1997;32:255–262.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Vitols S. Impaired low-density lipoprotein receptor activity in chronic B-lymphocytic leukaemia cells. Eur J Haematol 1988;40:18–24.
   PubMed Web of Science ®Google Scholar
• Chapman-Shimshoni D, Yuklea M, Radnay J, et al. Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Exp Hematol 2003;31:779–783.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Rabe KG, Kay NE, et al. Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia. Leuk Lymphoma 2010;51:1233–1240.
   PubMed Web of Science ®Google Scholar
• Friedman DR, Magura LA, Warren HA, et al. Statin use and need for therapy in chronic lymphocytic leukemia. Leuk Lymphoma 2010;51:2295–2298.
   PubMed Web of Science ®Google Scholar
• Cortes J, Hochhaus A, Hughes T, et al. Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J Clin Oncol 2011;29:524–531.
   PubMed Web of Science ®Google Scholar
• Yang YC, Huang WF, Chuan LM, et al. In vitro and in vivo study of cell growth inhibition of simvastatin on chronic myelogenous leukemia cells. Chemotherapy 2008;54:438–446.
   PubMed Web of Science ®Google Scholar
• Chen R, Xiao W, Li D, et al. Combination of simvastatin and imatinib sensitizes the CD34 + cells in K562 to cell death. Med Oncol 2011;28:528–531.
   PubMed Web of Science ®Google Scholar
• Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6:1399–1402.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Maas K, Youssef S, et al. Regulation of different inflammatory diseases by impacting the mevalonate pathway. Immunology 2009;127:18–25.
   PubMed Web of Science ®Google Scholar
• Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813–1826.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Youssef S, Baker J, et al. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood 2007;110:4588–4598.
   PubMed Web of Science ®Google Scholar
• Hori A, Kanda Y, Goyama S, et al. A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease. Transplantation 2005;79:372–374.
   PubMed Web of Science ®Google Scholar
• Hamadani M, Awan FT, Devine SM. The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. Blood 2008;111:3901–3902.
   PubMed Web of Science ®Google Scholar
• Rotta M, Storer BE, Storb R, et al. Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010;16: 1463–1466.
   PubMed Web of Science ®Google Scholar